Postoperative health-related quality of life (HR-QoL) significantly improves in patients undergoing hepatectomy for high-risk colorectal liver metastases if they remain disease-free. HR-QoL, as measured by the QLQ-C30, dropped by 14.6 points post-surgery but returned to baseline by 12 months. Patients with no evidence of disease (NED) showed marked improvement, reporting higher HR-QoL scores 24 months […]
Category: Intestine and Lower Gastrointestinal Tract
Compliance with Cancer Standard Improves Rectal Surgery Outcomes
Facility adherence to Commission on Cancer Standard 5.7 is linked to better surgical quality in rectal cancer. CRM positivity is lower at compliant facilities (12% vs 14%; adjusted OR 0.82, p=0.04). More patients achieved complete total mesorectal excision (TME) at compliant hospitals (adjusted OR 1.63, p=0.001); incomplete TME rates were also lower (9% vs 14%, […]
Assessing Secondary Cytoreductive Surgery for Colorectal Cancer
Secondary cytoreductive surgery with hyperthermic intraperitoneal chemotherapy improves survival for select patients with recurrent colorectal cancer peritoneal metastases. Patients undergoing secondary surgery had an overall survival of 51.0 months compared to 24.0 months for those with initial treatment alone. No difference in postoperative complications was observed between initial and secondary procedures. Consider secondary surgery for […]
Resecting Colorectal Liver Metastases in Progressive Disease Improves Survival
Surgery for colorectal liver metastases after chemotherapy failure can offer survival benefits. Patients with progressive disease underwent hepatectomy showed a 5-year overall survival rate of 42.7%. This is lower than those with controlled disease (62.0% in complete/partial response and 55.5% in stable disease, p<0.001). However, resected progressive disease patients had better survival (46.5%) than non-resected […]
Medicaid Expansion Lowers Death Rate in Colorectal Cancer Patients
Medicaid expansion is linked to improved survival rates in younger colorectal cancer patients with liver metastasis, impacting surgical decision-making. 3-year disease-specific mortality dropped from 75% to 68% in expansion states after 6+ years. Risk of death reduced by 5-10% in expansion states compared to non-expansion, particularly benefiting those who underwent liver metastasectomy (HR 0.71-0.85). Access […]
Acute Colonic Ischemia Risks After Colectomy for Cancer
Postoperative colonic ischemia is rare but significantly impacts outcomes after elective colectomy for colorectal cancer. Occurred in 0.27% of patients; highest rates seen in left hemicolectomy (0.52%) and transverse colectomy (0.47%). Patients with ischemia had a median Charlson comorbidity index of 3 versus 2 in those without (p < .001). It is linked to a […]
Biomarkers for Recurrent Rectal Cancer Outcomes
Identifying molecular biomarkers could enhance patient selection for salvage surgery in locally recurrent rectal cancer, impacting surgical strategies and patient outcomes. Locoregional recurrence rates after surgery ranged from 15% to 52% over 3-5 years. Five-year overall survival rates varied from 22% to 53%. Surgeons should consider serum biomarkers like CEA and CA19-9, linked to poor […]
Early Onset Colorectal Cancer Reveals Distinct Genomic Profile
Surgeons should note that early onset colorectal cancer (diagnosed before age 50) is distinct from late-onset cases, significantly impacting risk assessment and treatment. Analyzed data from nearly 20,000 patients showed a higher prevalence in distal and rectal sites, particularly among Hispanic and Asian populations. Early onset cases exhibit diverse genomic alterations, including higher rates of […]
NPWT after Stoma Reversal: Less Healing Time, No SSI Benefit
Negative pressure wound therapy (NPWT) doesn’t cut surgical site infections but speeds up healing after stoma reversal. No significant difference in surgical site infection rates (odds ratio: 1.02). Complete wound healing time reduced by about 2.72 days with NPWT. Consider NPWT for high-risk patients, as it can enhance recovery time without increasing infection risk. No […]
Cytoreductive Surgery and HIPEC Extend Survival for Colorectal Metastases
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) can significantly improve outcomes for patients with colorectal peritoneal metastases. Median overall survival with complete cytoreductive clearance is 43 months, compared to 10-18 months with systemic chemotherapy alone. Patients with the KRAS G12V mutation have a median overall survival of 34 months, significantly lower than the wild-type […]